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Background
The g-aminobutyric acid type A (GABAA) receptors are the
major inhibitory neurotransmitter receptors of the central
nervous system. Benzodiazepine (Bz)-site ligands bind at
the a/g interface and can enhance GABA-induced Cl− cur-
rents. The efficacy of certain benzodiazepines strongly
depends on the type of a(1,2,3,5) subunits in the receptors.
Functionally selective compounds for a2/3 can be anxioly-
tic without having the side effect of sedation. The molecular
basis for functional selectivity is investigated in this work.
Methods
Two-electrode voltage-clamp electrophysiology recordings
were performed in wild-type and mutated receptors
expressed in Xenopus laevis oocytes. Modelling, docking
and molecular dynamics simulation studies of a1g2 and
a3g2-containing receptors were performed to understand
Bz-ligand interaction with the different a subunits.
Results
Electrophysiology recordings identified flumazenil as a null
modulator in a1 and a weak plus modulator in a3-
containing receptors. A sequence comparison between the
a1 and a3 subunit revealed the residue R228 as unique
for the a3 subunit among all a subunits. a3R228A-
mutated receptors completely lost their ability to respond
to flumazenil. This amino acid is part of the so-called loop
C, a several-residues-spanning segment that forms part of
the ligand-binding site with a highly variable sequence.
The functionally a3-selective ligand flumazenil was
docked into the a/g interface. The flumazenil-bound state
in the a1 subtype has already been studied previously [1]
and was used for comparison. Our results indicate that the
binding mode of flumazenil in a1 and a3-containing
receptors is very similar.
Conclusions
The models made in this study show improved properties
in certain variable segments that could not be resolved in
the previously published models [1]. For understanding
the role of a3R228, more models and docking computa-
tions have to be made on the basis of these improvements
to explore possible conformations.
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